Core Insights - The company has developed new products in electronic accelerator, new materials, and optoelectronic chip businesses, indicating a strong focus on innovation and market expansion [1] Electronic Accelerator Business - The company has successfully developed the first domestic S-band 10MeV/32kW high-power industrial irradiation electronic accelerator for disinfection and sterilization, which offers higher power and processing efficiency compared to the traditional 20kW accelerator, meeting high-dose disinfection needs for high-capacity clients [1] New Materials Business - The company has independently developed and produced irradiation cross-linked ethylene-tetrafluoroethylene copolymer (XETFE), which has broad application prospects in aerospace and low-altitude economy, achieving domestic substitution for imported materials [1] Optoelectronic Chip Business - The company’s high-performance silicon photomultiplier packaging production line is set to be operational in the first half of 2025, showcasing advancements in the optoelectronic chip sector [1] Medical Health Business - The company is increasing R&D investment in medical health, focusing on developing a miniaturized proton therapy system, with technical breakthroughs and design plans already completed [1] - In the isotope sector, the company is conducting research on the production processes of copper-64 and zirconium-89 using accelerators, with plans for future industrialization based on market demand [1]

Group 1: Proton Medical Equipment and Isotope Production - Proton medical equipment from the Huaxi project has completed factory production, but installation is pending site readiness, with no acceptance expected this year [2] - The company is focusing on domestic isotope production, particularly the germanium-gallium generator, which is in a critical phase from technical breakthroughs to large-scale supply [2][3] - The company plans to produce isotopes such as germanium-68 and iodine-123, with stable delivery based on customer orders once production starts [3] Group 2: Research and Development Investments - The company has developed a high-power industrial irradiation electron accelerator for disinfection, which offers higher power and efficiency compared to traditional models [4] - New materials like XETFE, suitable for aerospace applications, have been developed, achieving small-scale sales and targeting both domestic and international markets [7] - The company is also advancing in the production of copper-64 and zirconium-89 isotopes, with plans for future industrialization based on market demand [4] Group 3: Financial Performance and Strategic Measures - The company has faced two consecutive years of losses but is implementing measures to reduce costs and increase revenue, including strategic collaborations with major clients [8] - Plans for product transformation and innovation enhancement are underway to align with market demands [8] - The company aims to improve operational efficiency through comprehensive reforms [8]